Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 23;9(8):e1599.
doi: 10.7759/cureus.1599.

Cost-Effectiveness of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium Difficile Infection: A Literature Review

Affiliations
Review

Cost-Effectiveness of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium Difficile Infection: A Literature Review

Leor T Arbel et al. Cureus. .

Abstract

Clostridium difficile (C. difficile) is a common cause of antibiotic--associated diarrhea (AAD), being responsible for 15--25% of all AAD cases. The purpose of this literature review is to determine the cost-effectiveness of fecal microbiota transplantation (FMT) and how it compares in this regard to the standard treatments of choice for recurrent C. difficile infection (CDI). The review of the literature along with the evaluation of three comparative cost effective analyses yielded findings consistent with the view that FMT is the most cost-effective option in treating recurrent CDI. There are some (but considerably less) data indicating that FMT may be a cost effective strategy in treating initial CDI, as well. The superior cost-effectiveness of FMT as compared to the preferred standards of treatment for recurrent CDI suggest FMT use should become more integrated in routine clinical practice. Increased utilization of FMTs would allow for better control of this increasingly problematic disease as well as lower costs associated with its management.

Keywords: antibiotics; c. difficle; cost effectiveness; diarrhea; fecal microbiota transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Frequently Asked Questions about Clostridium difficile for Healthcare Providers. [Sep;2017 ];https://www.cdc.gov/hai/organisms/cdiff/cdiff_faqs_hcp.html Centers for disease control and prevention. 2010
    1. Lamont JT. Uptodate. UpToDate; [Sep;2017 ]. 2014. Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology.
    1. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. Rao K, Safdar N. J Hosp Med. 2016;11:56–61. - PMC - PubMed
    1. Association of relapse of Clostridium difficile disease with BI/NAP1/027. Marsh JW, Arora R, Schlackman JL, et al. J Clin Microbiol. 2012;50:4078–4082. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Accessed; [Sep;2017 ]. 2015. Clostridium difficile Infection Information for Patients.

LinkOut - more resources